Left bundle branch area pacing guided by electroanatomical mapping in patients with structural heart disease and advanced conduction abnormalities

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Left bundle branch area pacing (LBBAP) can be technically challenging and fluoroscopy-intense, particularly in patients with structural heart disease (SHD) and advanced conduction abnormalities. Three-dimensional electroanatomical mapping (EAM) facilitates high-resolution, real-time, and non-fluoroscopic lead navigation, electrogram and pace mapping. PURPOSE: The purpose of the study was to prospectively evaluate the feasibility, safety, and outcomes of routine EAM-guided LBBAP in patients with SHD and advanced conduction abnormalities. METHODS: Consecutive patients with SHD and advanced conduction abnormalities (defined as second or third-degree atrioventricular (AV) block and/or complete bundle branch block) who underwent an attempt at EAM-guided LBBAP were included. EAM-guided lead implantation was performed in all patients following a standardized protocol irrespective of the pacing indication and type of conduction disturbance. The feasibility, safety, procedural and mid-term outcomes were evaluated. Electrical, echocardiographic, and clinical parameters were assessed at implantation and last follow-up. RESULTS: Thirty-two patients (68±18 years; 19% female) were included. The indication for pacing was cardiac resynchronization therapy in 50%, AV block in 44%, and pace-and-ablate in 6% of patients; 24 patients (75%) had an intrinsic QRS >150 ms, 17 (53%) had LBBB. Primary EAM-guided LBBAP was successful in 29 patients (91%). Procedural duration was 95 (70-110) min, total fluoroscopy time 0.93 (0.40-1.73) min, and total fluoroscopy dose 35.4 (20.5-77.2) cGycm2 (Figure 1A). The paced QRS duration during LBBAP was significantly shorter than the baseline intrinsic QRS duration (121.9±10.7 vs. 159.2±34.4 ms; p<0.001) (Figure 1B) and remained stable (120.3±11.1 ms; p=0.370) during a mean follow-up of 7.0±5.9 (median 5.4 [IQR 2.1-12.6]) months. LBBAP capture threshold was 0.57±0.23V/0.4ms at implantation and remained low during follow-up (0.58±0.18V/0.5±0.2ms; p=0.877). There was no increase in LBBAP capture threshold >1.0V/0.4 ms during follow-up. Overall LVEF improved significantly from 44.2±14.3% at baseline to 49.4±13.1% at last follow-up (p=0.009), NYHA functional class from 2.4±0.6 to 1.8±0.6 (p=0.002), respectively (Figure 1C+D). No complications occurred that required intervention. CONCLUSION: Routine near-zero fluoroscopy EAM-guided LBBAP can safely be performed in patients with SHD and advanced conduction abnormalities with high success rates and favourable mid-term outcomes. Further studies are needed to investigate whether the use of EAM improves overall outcome of conduction system pacing, and to identify specific patient populations who benefit the most from EAM-guided lead implantation. [Figure: see text]